Acceleron said it will start the first regenerative therapeutic to enter human clinical trials from Acceleron's scientific platform that utilizes the body's own naturally-occurring growth factors.
“Based on extensive evidence from preclinical studies, ACE-011 has the potential to rebuild bone even after substantial bone loss has already occurred. The preclinical data strongly suggests that ACE-011 could fundamentally change the treatment of bone loss,” said Dr Jasbir Seehra, chief scientific officer and a founder of Acceleron.
Acceleron is conducting the phase I study in healthy post-menopausal women. The study is a randomized, placebo-controlled, a single ascending dose study designed to evaluate safety, tolerability, and pharmacology properties of ACE-011.
Following the phase I study of ACE-011, Acceleron will introduce other regenerative drug candidates into clinical development and will continue to build integrated pharmaceutical capabilities to develop these candidates into new therapies.